Home›Companies›Biotech & Pharma›Fairfield Bio

Fairfield Bio, Inc.

A genomic data marketplace connecting data providers with researchers and industry.

Updated Nov 9, 2026·Latest SEC filing Oct 6, 2026·Suggest an edit

About Fairfield Bio

Fairfield Bio is a private company based in Bronx, New York, incorporated in 2025 in Delaware. It has reported $1,945,000 raised in one offering on Form D since February 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 26, 2026Feb 12, 2026amended Oct 6, 2026$1,945,000of $3.0M target11$176KSecurities on exerciseRule 506(b)Form D/A ↗1 earlier filing

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Fairfield Bio's Form D filed Oct 6, 2026.

KS
Kevin Slavin
President and director
MW
Mitchell Wolfe
Executive officer and director

Sources

  1. SECFairfield Bio, Inc. Form D, filed Feb 12, 2026
  2. SECFairfield Bio, Inc. filing history